After Eli Lilly’s phase 3 data drop for its oral GLP-1 asset orforglipron earlier this month, the Indianapolis drugmaker has unveiled the second half of the data package that will support the med’s | ...

One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...

The Phase II VENTURE-Oral Dosing study of VK2735 met primary and secondary endpoints, with once-daily treatment leading to progressive weight reductions, high responder rates, and encouraging safety ...

Serena Williams has a new doubles partner. The 23-time Grand Slam tennis champion is working with Ro, speaking out about how ...

Individuals with diabetes were not included in the study. The 3,127 trial participants were randomized to receive either 6 mg, 12 mg or 36 mg of the GLP-1 receptor agonist orforglipron or placebo.

An oral GLP-1 induced up to 12.4% weight loss at 72 weeks for adults with overweight or obesity, according to topline results from the phase 3 ATTAIN-1 trial. As Healio previously reported ...

A new oral GLP-1 drug candidate could transform the diabetes and weight loss drug boom. Why it matters: Eli Lilly said on Thursday that its experimental pill — called orforglipron — is showing ...

Novo said 44% of people treated with 0.5 mg semaglutide compared with 23% of people treated with 0.75 mg dulaglutide achieved more or equal to 5% body weight loss and 63% of people with 1.0 mg ...

Eli Lilly (LLY) reported better-than-expected earnings for the second quarter on Thursday. But disappointing results of its much-awaited oral GLP-1 pill sent the stock down 13% in early trading. The ...

Lilly's Kwikpen debut intensifies rivalry with Novo Nordisk's Wegovy in the world's most populous diabetes market ...